Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 31.35 is 65% above its 5-year average of 19.04, near the high end of its 5-year range (5.61–34.33).
As of the fiscal period ended Tuesday, June 30, 2026. 15.95% above its 12-month average of 27.04.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 31.35.
QUICK RATIO (ACID-TEST)
31.35
QUICK RATIO (ACID-TEST) AVG TTM
27.04
QUICK RATIO (ACID-TEST) AVG 3Y
23.30
QUICK RATIO (ACID-TEST) AVG 5Y
19.04
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+15.95%
CURRENT VS 3Y AVG
+34.55%
CURRENT VS 5Y AVG
+64.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 563 covered companies
CURRENT VS SECTOR MEDIAN
+948.52%
vs the sector median at left
Fulcrum Therapeutics, Inc.
Market Cap
$281.16M
Quick Ratio (Acid-Test)
31.35
TTM Avg
27.04
3Y Avg
23.30
5Y Avg
19.04
Market Cap
$279.74M
Quick Ratio (Acid-Test)
4.85
TTM Avg
6.69
3Y Avg
6.56
5Y Avg
6.64
Market Cap
$285.98M
Quick Ratio (Acid-Test)
6.40
TTM Avg
6.41
3Y Avg
5.95
5Y Avg
4.92
Market Cap
$276.26M
Quick Ratio (Acid-Test)
2.80
TTM Avg
2.74
3Y Avg
2.22
5Y Avg
2.48
Market Cap
$287.58M
Quick Ratio (Acid-Test)
4.69
TTM Avg
11.27
3Y Avg
11.27
5Y Avg
11.27
Market Cap
$274.05M
Quick Ratio (Acid-Test)
19.48
TTM Avg
1.73
3Y Avg
4.11
5Y Avg
4.35
Market Cap
$290.87M
Quick Ratio (Acid-Test)
4.70
TTM Avg
5.10
3Y Avg
7.75
5Y Avg
8.34
Market Cap
$266.50M
Quick Ratio (Acid-Test)
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
Market Cap
$265.63M
Quick Ratio (Acid-Test)
0.93
TTM Avg
1.36
3Y Avg
5.78
5Y Avg
8.29
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $281.16M | 31.35 | 27.04 | 23.30 | 19.04 |
| Fate Therapeutics, Inc. (FATE)vs › | $279.74M | 4.85 | 6.69 | 6.56 | 6.64 |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.98M | 6.40 | 6.41 | 5.95 | 4.92 |
| Aurora Cannabis Inc. (ACB)vs › | $276.26M | 2.80 | 2.74 | 2.22 | 2.48 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $287.58M | 4.69 | 11.27 | 11.27 | 11.27 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.05M | 19.48 | 1.73 | 4.11 | 4.35 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.87M | 4.70 | 5.10 | 7.75 | 8.34 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.50M | 16.00 | 13.11 | 8.33 | 7.81 |
| AC Immune S.A. (ACIU)vs › | $265.63M | 0.93 | 1.36 | 5.78 | 8.29 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | 15.82 | 24.04 | 14.70 | 12.06 |
Quick Ratio
31.35
Excludes inventory
Current Ratio
31.35
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 31.35 |
| 2026-03-31 | 34.33 |
| 2025-12-31 | 27.40 |
| 2025-09-30 | 17.70 |
| 2025-06-30 | 24.42 |
| 2025-03-31 | 28.71 |
| 2024-12-31 | 22.63 |
| 2024-09-30 | 18.44 |
| 2024-06-30 | 22.07 |
| 2024-03-31 | 20.38 |
| 2023-12-31 | 17.71 |
| 2023-09-30 | 18.65 |
| 2023-06-30 | 19.11 |
| 2023-03-31 | 21.02 |
| 2022-12-31 | 12.46 |
| 2022-09-30 | 15.49 |
| 2022-06-30 | 7.88 |
| 2022-03-31 | 10.94 |
| 2021-12-31 | 11.77 |
| 2021-09-30 | 11.75 |
| 2021-06-30 | 5.61 |
| 2021-03-31 | 6.40 |
| 2020-12-31 | 4.33 |
| 2020-09-30 | 4.83 |
| 2020-06-30 | 9.53 |
| 2020-03-31 | 5.78 |
| 2019-12-31 | 8.00 |
| 2019-09-30 | 11.89 |
| 2019-06-30 | 7.87 |
| 2019-03-31 | 13.49 |
| 2018-12-31 | 17.39 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
